ARTICLE | Clinical News
Lemborexant: Ph II started
November 10, 2016 11:21 PM UTC
Eisai began the double-blind, placebo-controlled, international Phase II Study 202 to evaluate 2.5, 5, 10 and 15 mg oral lemborexant for 4 weeks in about 125 patients ages 65-90 with ISWRD and mild to...